View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Ben Harwood ... (+2)
  • Ben Harwood
  • Pierre FerraguÊ

Tariffs: Autos, Industrials, and Infineon: the baseline & what's next

Evaluating the consequences of tariffs is challenging. As we strengthen our understanding of the tech supply chain, we follow-up on our initial analysis to evaluate the impact on Infineon, as well as the broader Auto and Industrial market. This note follows recent ones we published on Nvidia, Broadcom, Intel/AMD, Semicap & TSMC. Read also our broader notes on tariffs: our baseline thesis for an overall perspective, and our assessment of the macro risk.

 PRESS RELEASE

argenx to Report First Quarter 2025 Financial Results and Business Upd...

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...

 PRESS RELEASE

Availability of 2024 Universal Registration Document and Procedure for...

Availability of 2024 Universal Registration Document and Procedure for Consulting Preparatory Documents for General Shareholders’ Meeting AVAILABILITY OF 2024 UNIVERSAL REGISTRATION DOCUMENT AND PROCEDURE FOR CONSULTING PREPARATORY DOCUMENTS FOR GENERAL SHAREHOLDERS’ MEETING April 30, 2025 - The 2024 Universal Registration Document (Document d’Enregistrement Universel) of Publicis Groupe S.A. [Euronext Paris FR0000130577, CAC 40] has been filed with the French Financial Markets Regulatory Authority (AMF) on April 30, 2025. The document can be requested at the Groupe’s Headquarter in accor...

 PRESS RELEASE

Mise à disposition du Document d’Enregistrement Universel 2024 et moda...

Mise à disposition du Document d’Enregistrement Universel 2024 et modalités de consultation des documents préparatoires de l’Assemblée Générale MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2024 ET MODALITÉS DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES DE L’ASSEMBLÉE GÉNÉRALE 30 avril 2025 - Le Document d’Enregistrement Universel de Publicis Groupe S.A. [Euronext Paris FR0000130577, CAC 40] pour l’année 2024 a été déposé à l’Autorité des Marchés Financiers le 30 avril 2025. Il est tenu à la disposition du public dans les conditions prévues par la réglementation en vigueur et ...

 PRESS RELEASE

Disclosure of trading in own shares

Disclosure of trading in own shares Disclosure of trading in own shares on 04/25/2025 Paris – April 29, 2025 Share repurchase program approved by the Shareholders’ Meeting of May 29, 2024 Transaction Details: Publicis Groupe SA Name of the Issuer Identity Code of the Issuer ISIN Intermediary Name Identify Code of the Intermediary Currency Publicis Groupe SA 2138004KW8BV57III342 FR0000130577 BOFA SECURITIES EUROPE SA 549300FH0WJAPEHTIQ77 EUR Total number of shares purchased according to trading venues: Name of the Issuer Identity code of the financial instrument Day of th...

 PRESS RELEASE

Déclaration des transactions sur actions propres

Déclaration des transactions sur actions propres Déclaration des transactions sur actions propres réalisées le 25/04/2025 Paris – 29 avril 2025 Programme de rachat d’actions adopté par l’Assemblée Générale du 29 mai 2024 Détails des Transactions pour Publicis Groupe SA Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Code identifiant de l'instrument financier (ISIN) Nom du PSI Code identifiant du PSI Devise Publicis Groupe SA 2138004KW8BV57III342 FR0000130577 BOFA SECURITIES EUROPE SA 549300FH0WJAPEHTIQ77 EUR Nombre total d'actions rachetées par place de marché:...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch